ESRRA and breast cancer: Importantly, pharmacological inhibition of ERRα further sensitized BC cells in vitro and in vivo to the anti-neoplastic effects of the DNMT inhibitor 5-aza-2′-deoxycytidine (decitabine, 5-AzadC).